Artificial intelligence (AI) has become a hot topic, making its way into everyday conversations and industries worldwide. While AI technologies have been around for years, recent advancements are accelerating their impact—especially in healthcare. From improving cancer research to enhancing diagnosis and treatment, AI is reshaping the future of medicine. In this episode of NETWise, we dive into how AI is driving progress in neuroendocrine cancer research and explore its potential applications in the clinic. Could AI revolutionize the way NETs are diagnosed and managed? Join us as we uncover the possibilities.

To access the NET Clinical Trial Finder mentioned in this episode: https://netrf.org/for-patients/trial-finder/

Danielle Ralic is the CEO/CTO and founder of Ancora.ai, a health tech company dedicated to accelerating innovation in medicine by democratizing clinical trial access. Her service uses AI to help neuroendocrine cancer patients find clinical trials.

Matthieu Foll, PHD is a researcher at  the International Agency for Research and Cancer, part of the World Health Organization.

Emilie Mathian, PHD is a postdoctoral researcher at the International Agency for Research on Cancer (IARC-WHO)

Dr.  Aman Chauhan, MD, is a medical oncologist at the University of Miami Sylvester Comprehensive Cancer Center, where he leads the neuroendocrine oncology program and co-directs theranostic drug development.

The post NETWise Episode 43: How Could AI Change Neuroendocrine Cancer? appeared first on NETRF.